DOT-C: A cluster randomised feasibility trial evaluating d irectly o bserved an t i-H C V therapy in a population receiving opioid substitute therapy from community pharmacy-Reference-Cited by-同舟云学术

DOT-C: A cluster randomised feasibility trial evaluating d irectly o bserved an t i-H C V therapy in a population receiving opioid substitute therapy from community pharmacy

Published:2017-09 Issue: Volume:47 Page:126-136
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

Radley Andrew^ORCID,Tait Jan,Dillon John F.

Publisher

Elsevier BV

Subject

Health Policy,Medicine (miscellaneous)

Reference52 articles.

1. Community pharmacy and public health in Great Britain 1937–2006: How a phoenix rose from the ashes;Anderson;Journal of Epidemiology and Public Health,2007

2. The contribution of community pharmacy to improving the public’s health: Summary report of the literature review 1990–2007. Pharmacy Health Link;Anderson,2009

3. Evaluation of a general practice Hepatitis C virus screening intervention;Anderson;Scottish Medical Journal,2009

4. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection;Arain;World Journal of Gastroenterology,2014

5. What is a pilot or feasibility study? A review of current practice and editorial policy;Arain;BMC Medical Research Methodology,2010

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The implementation of a hepatitis C testing service in community pharmacies: I-COPTIC consensus statement;Public Health;2024-07

2. ‘I just never wanted them to feel uncomfortable’: Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada;Canadian Liver Journal;2024-05-08

3. Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis;eClinicalMedicine;2024-03

4. Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts;BMC Public Health;2023-01-07

5. Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugs;International Journal of Drug Policy;2023-01